Table 1.
FDA approved drugs targeting VEGF/VEGFR pathways
| Name | Company | Type | Main target(s) | Approved for |
|---|---|---|---|---|
| Bevacizumab (Avastin) | Genentech/Roche | Humanized monoclonal antibody | VEGF-A | Metastatic colorectal carcinoma, non-small cell lung carcinoma, advanced glioblastoma, metastatic renal cell carcinoma |
| Sorafenib (Nexavar) | Bayer/Onyx | Small molecule TK inhibitor | VEGFR, PDGFR, Raf, cKit, FLT3 | Advanced renal cell and hepatocellular carcinomas |
| Axitinib (Inlyta) | Pfizer | Small molecule TK inhibitor | VEGFR, PDGFR, cKit | Renal cell carcinoma |
| Pazopanib (Votrient) | GSK | Small molecule TK inhibitor | VEGFR, PDGFR, cKit | Advanced renal cell carcinoma, soft tissue sarcoma |
| Vandetanib (Caprelsa) | AstraZeneca | Small molecule TK inhibitor | VEGFR, EGFR, RET | Medullary thyroid cancer |
| Zaltrap (VEGF trap) | Regeneron/Sanofi-aventis | Fusion protein of Fc with VEGFR1 and R2 domains | VEGF, PlGF | Metastatic colorectal cancer |
| Ramucirumab (Cyramza) | Lilly/Imclone | Human monoclonal antibody | VEGFR2 | Gastric/gastroesophageal junction adenocarcinoma, colorectal carcinoma, non-small cell lung carcinoma |